A decade of immune-checkpoint inhibitors in cancer therapy
Immunotherapy using immune-checkpoint modulators revolutionizes the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes in the evaluation of treatment efficacy and toxicity with a more holistic vision of the patient with cancer.
Guardado en:
Autor principal: | Caroline Robert |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c42a3252354844d2a513889832446b69 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Indicators of responsiveness to immune checkpoint inhibitors
por: Bradley D. Shields, et al.
Publicado: (2017) -
Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity
por: Marka R. Crittenden, et al.
Publicado: (2018) -
Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency
por: Katsunori Manaka, et al.
Publicado: (2021) -
Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
por: Marina A. Lyadova, et al.
Publicado: (2021) -
Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment
por: Tae Heung Kang, et al.
Publicado: (2020)